RxDoctor Payments Data

Matthew Krafft, MD

Gastroenterology · Morgantown, WVNPI 1477965135

Payments from drug & device makers

What this record shows

This record is dominated by grants: $25,000 of the $27,533 with a category attached, or 90.8%. Boston Scientific accounts for 92.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2021 at $25,000 and has fallen 97.0% since, to $749 in 2025.

$27,533in general payments, 2019–2025

Across 32 payments — averaging $860.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$26K
  • Olympus Corporation Of The Americas$874
  • Medtronic$567
  • Conmed Corporation$164
  • AbbVie$126
  • Steris Corporation$122
  • plus $122 from 5 others

What the payments were for

  • Grants$25,00091%
  • Travel & lodging$6702%
  • Food & beverage$1,8627%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,533 in reported general payments places this provider in the 85th percentile of 72 gastroenterology providers in West Virginia.

See all gastroenterology providers in West Virginia

Medicare billing

Part B allowed, 2024
$120,772
Medicare patients
375
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab17$464,655
Omeprazole25$339
Pantoprazole Sodium24$310
Ondansetron OdtOndansetron13$302
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg12$227
Promethazine Hcl12$63
Tramadol Hcl32$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$29$464,65517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 72 gastroenterology providers in West Virginia.

Other gastroenterology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →